Rachita Navara

Rachita Navara

Auto-generated profile, based on publicly available information

Rachita Navara

VA North Texas Healthcare System and University of Texas Southwestern Medical Center, Dallas, TX, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DZDavid M. Zhang
David M. Zhang
RNRachita Navara
Rachita Navara
TYTiankai Yin
Tiankai Yin
JSJeffrey Szymanski
Jeffrey Szymanski
UGUri Goldsztejn
Uri Goldsztejn
SRStacey Rentschler
Stacey Rentschler
Cardiac radiotherapy (RT) may be effective in treating heart failure (HF) patients with refractory ventricular tachycardia (VT). The previously proposed mechanism of radiation-induced fibrosis does not explain the rapidity and magnitude with which VT reduction occurs clinically. Here, we demonstrate in hearts from RT patients that radiation does not achieve transmural fibrosis within the timeframe of VT reduction. Electrophysiologic assessment of irradiated murine hearts reveals a persistent supraphysiologic electrical phenotype, mediated by increases in NaV1.5 and Cx43. By sequencing and transgenic approaches, we identify Notch signaling as a mechanistic contributor to NaV1.5 upregulation after RT. Clinically, RT was associated with increased NaV1.5 expression in 1 of 1 explanted heart. On electrocardiogram (ECG), post-RT QRS durations were shortened in 13 of 19 patients and lengthened in 5 patients. Collectively, this study provides evidence for radiation-induced reprogramming of cardiac conduction as a potential treatment strategy for arrhythmia management in VT patients.

1 May 2018 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
TBTina Baykaner
Tina Baykaner
ARAlbert J. Rogers
Albert J. Rogers
GMGabriela L. Meckler
Gabriela L. Meckler
JZJunaid Zaman
Junaid Zaman
RNRachita Navara
Rachita Navara
PHPaul A. Heidenreich
Paul A. Heidenreich
Background: The outcomes from pulmonary vein isolation (PVI) for atrial fibrillation (AF) are suboptimal, but the benefits of additional lesion sets remain unproven. Recent studies propose ablation of AF drivers improves outcomes over PVI, yet with conflicting reports in the literature. We undertook a systematic literature review and meta-analysis to determine outcomes from ablation of AF drivers in addition to PVI or as a stand-alone procedure. Methods: Database search was done using the terms atrial fibrillation and ablation or catheter ablation and driver or rotor or focal impulse or FIRM (Focal Impulse and Rotor Modulation). We pooled data using random effects model and assessed heterogeneity with I 2 statistic. Results: Seventeen studies met inclusion criteria, in a cohort size of 3294 patients. Adding AF driver ablation to PVI reported freedom from AF of 72.5% (confidence interval [CI], 62.1%–81.8%; P <0.01) and from all arrhythmias of 57.8% (CI, 47.5%–67.7%; P <0.01). AF driver ablation when added to PVI or as stand-alone procedure compared with controls produced an odds ratio of 3.1 (CI, 1.3–7.7; P =0.02) for freedom from AF and an odds ratio of 1.8 (CI, 1.2–2.7; P <0.01) for freedom from all arrhythmias in 4 controlled studies. AF termination rate was 40.5% (CI, 30.6%–50.9%) and predicted favorable outcome from ablation( P <0.05). Conclusions: In controlled studies, the addition of AF driver ablation to PVI supports the possible benefit of a combined approach of AF driver ablation and PVI in improving single-procedure freedom from all arrhythmias. However, most studies are uncontrolled and are limited by substantial heterogeneity in outcomes. Large multicenter randomized trials are needed to precisely define the benefits of adding driver ablation to PVI.

27 September 2022 in Cardiovascular Digital Health Journal
Verified
Journal Article
Open access
RKRajesh Kabra
Rajesh Kabra
SISharat Israni
Sharat Israni
BVBharat Vijay
Bharat Vijay
CBChaitanya Baru
Chaitanya Baru
RMRaghuveer Mendu
Raghuveer Mendu
DLDhanunjaya Lakkireddy
Dhanunjaya Lakkireddy
Artificial intelligence (AI) and machine learning (ML) have significantly impacted the field of cardiovascular medicine, especially cardiac electrophysiology (EP), on multiple fronts. The goal of this review is to familiarize readers with the field of AI and ML and their emerging role in EP. The current review is divided into 3 sections. In the first section, we discuss the definitions and basics of AI, ML, and big data. In the second section, we discuss their application to EP in the context of detection, prediction, and management of arrhythmias. Finally, we discuss the regulatory issues, challenges, and future directions of AI in EP.

29 October 2024 in Communications Medicine
Verified
Journal Article
Open access
PDF file
ASArun R. Sridhar
Arun R. Sridhar
JCJim W. Cheung
Jim W. Cheung
RLRachel Lampert
Rachel Lampert
JSJennifer N. A. Silva
Jennifer N. A. Silva
RGRakesh Gopinathannair
Rakesh Gopinathannair
DLDhanunjaya Lakkireddy
Dhanunjaya Lakkireddy
The rapid growth in consumer-facing mobile and sensor technologies has created tremendous opportunities for patient-driven personalized health management. The diagnosis and management of cardiac arrhythmias are particularly well suited to benefit from these easily accessible consumer health technologies. In particular, smartphone-based and wrist-worn wearable electrocardiogram (ECG) and photoplethysmography (PPG) technology can facilitate relatively inexpensive, long-term rhythm monitoring. Here we review the practical utility of the currently available and emerging mobile health technologies relevant to cardiac arrhythmia care. We discuss the applications of these tools, which vary with respect to diagnostic performance, target populations, and indications. We also highlight that requirements for successful integration into clinical practice require adaptations to regulatory approval, data management, electronic medical record integration, quality oversight, and efforts to minimize the additional burden to health care professionals.

1 October 2016 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
DSDaniel P. Sherbet
Daniel P. Sherbet
GCGeorgios Christopoulos
Georgios Christopoulos
AKAris Karatasakis
Aris Karatasakis
BDBarbara Anna Danek
Barbara Anna Danek
AKAnna Kotsia
Anna Kotsia
EBEmmanouil Brilakis
Emmanouil Brilakis

1 August 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
TBTina Baykaner
Tina Baykaner
TZTheodoros A. Zografos
Theodoros A. Zografos
JZJunaid A.B. Zaman
Junaid A.B. Zaman
IPIoannis Pantos
Ioannis Pantos
MAMahmood Alhusseini
Mahmood Alhusseini
DKDemosthenes G. Katritsis
Demosthenes G. Katritsis